Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder

Phase 2

Completed

Brief Summary: The purpose of this study is to assess the long-term safety, tolerability and efficacy of oral OPC-34712 as adjunctive therapy in the treatment of adult patients with Major Depressive Disorder (MDD).

Recruitment & Eligibility

Inclusion Criteria

Male or female subjects between 18 and 65 years of age, with a diagnosis of a single or recurrent, non-psychotic episode of major depressive disorder, as defined by DSM-IV-TR criteria and confirmed by the Mini International Neuropsychiatric Interview (M.I.N.I.) which is equal to or greater than 8 weeks in duration.
Subjects must currently be taking allowable antidepressant therapy at an adequate dose for a minimum of six weeks by the end of the screening period (ie at the time of the Baseline visit).
Subjects must report a history for the current depressive episode of an inadequate response to at least one and no more than four adequate antidepressant treatments.

Exclusion Criteria

Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug.
Subjects who report an inadequate response to more than three adequate trials of antidepressant treatments during current depressive episode at a therapeutic dose for an adequate duration.
Subjects with a current Axis I (DSM-IV-TR) diagnosis of: Delirium, dementia,amnestic or other cognitive disorder Schizophrenia, schizoaffective disorder, or other psychotic disorder Bipolar I or II disorder, eating disorder (including anorexia nervosa or bulimia), obsessive compulsive disorder, panic disorder, post-traumatic stress disorder.
Subjects with a clinically significant current Axis II (DSM-IV-TR) diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder.

Arm && Interventions

Group	Intervention	Description
OPC-34712 + ADT	OPC-34712	Experimental: OPC-34712, Oral Tablets, 0.25 - 3 mg; Antidepressant drug treatment
OPC-34712 + ADT	ADT	Experimental: OPC-34712, Oral Tablets, 0.25 - 3 mg; Antidepressant drug treatment

Primary Outcome Measures

Name	Time	Method
Participants With Adverse Events (AEs).	After the Informed Consent Form (ICF) was signed, through Follow up 30 (+2) days after last visit	An AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a participant while enrolled in the trial, whether or not it was considered drug-related by the physician. The severity was assessed as mild, moderate, or severe. A treament-emergent AE (TEAE) was defined as any AE that started after start of open-label brexpiprazole; or if the event was continuous from baseline and was worsening, serious, study drug-related, or resulted in death, discontinuation, interruption, or reduction of study drug.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Scale Score.	Week 1, 2, 4, 6, 8, 14, 20, 26, 32, 38, 44, 52 and 52 (last-observation-carried-forward [LOCF])	The CGI-S is a 7-point scale from 1 through 7. The items on CGI-S scale are: 0 = not assessed, 1 = normal, not at all ill, 2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill participants. The score 0 (= not assessed) was set to missing.
Mean Clinical Global Impression - Improvement (CGI-I) Scale Score.	Week 1, 2, 4, 6, 8, 14, 20, 26, 32, 38, 44, 52 and 52 (LOCF)	The items on CGI-I scale are 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse. The score of 0 (= not assessed) was set to missing. The CGI-I is therefore a 7-point scale from 1 through 7. CGI improvement was compared to the participants condition at Baseline.

Locations (32): Pacific Clinical Research Medical Group
🇺🇸
Arcadia, California, United States
Artemis Institute for Clinical Research
🇺🇸
San Diego, California, United States
California Neuroscience Research Medical Group, Inc.
🇺🇸
Sherman Oaks, California, United States
Gulfcoast Clinical Research Center
🇺🇸
Fort Myers, Florida, United States
Clinical Neuroscience Solutions
🇺🇸
Jacksonville, Florida, United States
Florida Clinical Research Center
🇺🇸
Maitland, Florida, United States
Clinical Neurosciences Solutions
🇺🇸
Orlando, Florida, United States
Stedman Clinical Trials
🇺🇸
Tampa, Florida, United States
Carman Research
🇺🇸
Smyrna, Georgia, United States
Goldpoint Clinical Research, LLC
🇺🇸
Indianapolis, Indiana, United States
Scroll for more (22 remaining)
Pacific Clinical Research Medical Group
🇺🇸Arcadia, California, United States